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Objectives: The fast-rising rate of diabetes incidents is a growing concern in Central Asian
countries. This article reviews the current understanding of type 2 diabetes etiology, progression
and treatment options along with opportunities for utilizing Avicenna’s legacy in developing
novel botanical therapeutics. Methods: Analysis of relevant publications, including a variety of
Avicenna’s work in Arabic, English and Russian. Results: With conventional treatment strategy
shifting from single-component drugs aimed at one target to multitherapeutic combinations
addressing the complex nature of many diseases and conditions, the role of multicomponent
botanical preparations may increase. Diabetes mellitus is a serious chronic, progressive disease
characterized by hyperglycemia, which is associated with a variety of comorbidities because
of considerable damage, dysfunction and failure of multiple organs developed through the
disease’s progression. Multidisciplinary collaborative research that encompasses innovative
tools could be used for effective development of new comprehensive therapeutic products
and treatments based on knowledge of traditional medicine and supported by contemporary
scientific validation. Conclusion: Comprehensive analysis of Avicenna’s 1,000-year-old
approach to the treatment of prediabetes and diabetes provides valuable directions in the
search for plant-based treatments. Botanical therapeutics may provide relatively inexpensive
and safe methods for diabetes treatment.
Keywords: Diabetes Mellitus, Ethnopharmacology, Traditional Medicine, Medicinal Plants,
Metabolic Acidosis, Ibn Sina

Introduction
Pancreatic β-cell dysfunction and insulin resistance in target
organs are the major characteristics of type 2 diabetes mellitus
(T2DM), the disease that causes profound psychological and
physical distress in patients and puts an enormous burden
200
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on health-care systems. Recent advances in understanding
comprehensive molecular and physiological mechanism
of glucose metabolism regulations and insulin resistance
causalities opened new opportunities in search for anti-diabetic
therapeutics and life-style modifications. With conventional
treatment strategy shifting from single-component drugs aimed
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at one target to multitherapeutic combinations addressing the
complex nature of many diseases and conditions, the role of
multicomponent botanical preparations may increase. The indepth analysis of Avicenna’s approach to diabetes treatment in
combination with contemporary drug development methodology
leads to streamlining botanical therapeutics development. Novel
botanical therapeutics are essential for reducing the
disease burden and T2DM prevention.
Central Asia is a vast geographic region with a rich history
whose countries are closely related through its nomadic peoples,
e.g., the Silk Road, and the Mongol and Russian Empire [1].
Abu 'Ali al-Husayn Ibn Abdullah Ibn al-Hasan Ibn 'Ali Ibn Sina
(980-1037), better known in the western literature as Avicenna,
influenced multiple generations of physicians. His evidencebased medicinal methodology, ideas and treatment methods are
still very popular in Central Asia and make up the foundation
of Unani medicine. There is growing interest in reassessing
and conducting a deep analysis of the Avicenna’s medical
magnum opus – “The Canon of Medicine” (al-QãnûnfÎ alTibb) [2-4]. Indeed, acceptance of Avicenna’s medicine requires
understanding of his medical system, avoiding misunderstandings
linked to improper translations or misinterpretations, adopting
practices and recognition of the evidence-based medicine
practiced millennia ago [2, 4]. “The Canon of Medicine” of
Avicenna, originally written in Arabic, is a very well-structured
source of many theoretical and practical branches of medieval
medicine, and a repository of ideas, many of which remain not
completely decrypted and may be relevant to modern medicine
[5, 6]. After the translation and publication of “The Canon of
Medicine” in Latin, English, Russian, Tajik, Persian, Uzbek and
many other languages, this magnum opus has reached millions
of readers. This encyclopedic work is not easy to comprehend
and it is still full of unsolved and not yet deciphered secrets.
Translation and interpretation of the medieval Arabic text are
substantial problems and require not only exceptional language
skills and an understanding of ancient medical practices, but
also a broad knowledge of modern science. Unfortunately,
English translations did not use the original Arabic text, but they
were done from other translations (Latin, Urdu, and Farsi) and
failed to capture the spirit of the book [2]. It is also important to
emphasize that in 2012 non-communicable diseases including
diabetes have been the highest-ranking causes in Central Asian
countries in terms of disability-adjusted life years and years
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of life lost [1]. In this article, we review current approaches to
diabetes treatment and prevention and explore how Avicenna’s
views may help in managing the modern T2DM epidemic.

Materials and Methods
This review is based on a thorough analysis of the literature in
English, Russian, Arabic, and Tajik. The appropriate searches were
conducted in Google Scholar (scholar.google.com), PubMed
(www.ncbi.nlm.nih.gov/pubmed), KiberLeninka (cyberleninka.
ru), eLIBRARY (elibrary.ru). We also used materials available
at the Russian National Library (Moscow, Russia) and Central
Agricultural Science Library (Moscow Russia). The Institute of
Avicenna’s Medicine and Pharmacology (Dushanbe, Tajikistan)
and the Institute of Philosophy, Political Science and Human
Rights of the Academy of Sciences of the Republic of Tajikistan
graciously provided access to the books authored by Avicenna.

Results
1. Diabetes
Diabetes mellitus (DM), often referred to as simply diabetes, is
a serious chronic, progressive disease characterized by elevated
levels of serum glucose (hyperglycemia) (Figure 1), which is
associated with a variety of comorbidities, such as blindness,
poor wound healing, erectile dysfunction, kidney failure, heart
disease, etc; caused by considerable damage, dysfunction,
and failure of multiple organs developed through the disease
progression. DM occurs either when pancreatic cells do not
produce sufficient amount of insulin, or when the cells of the
body do not respond properly to the produced insulin. Globally,
DM caused over 1.5 million deaths in 2012 and an estimated
8.5% of the adult population (422 million people) were living
with diabetes in 2014 with 30.3 million people or 9.4% in the
US in 2015 [7, 8]. Out of three generally recognized DM types
(type 1 or “insulin-dependent diabetes,” type 2 or “non-insulindependent diabetes,” and gestational diabetes), type 2 (T2DM)
is the most prominent constituting about 90% of all cases.
T2DM is a growing healthcare burden primarily due to longterm complications. Acute complications can include diabetic
ketoacidosis, nonketotic hyperosmolar coma, or even death.
Serious long-term complications include heart disease, stroke,
chronic kidney failure, foot ulcers, and damage to the eyes. For
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example, among adults in China, diabetes was associated with
increased mortality from a range of cardiovascular and noncardiovascular diseases. The prevalence of diabetes in China has
more than quadrupled in recent decades, with an estimated 110
million adults having diabetes in 2010 and 490 million adults
estimated to have prediabetes [9]. The Republican Clinical
Endocrinology Center reports 37,691 people officially diagnosed
with diabetes in Tajikistan in 2016, with disease prevalence
for different districts ranging from 280 to 678 per 100,000
population. In Mongolia, T2DM is growing problem and a
generally poor glycemic control in patients has been reported
[10]. It is estimated that worldwide by 2040 one in 10 adults
will have diabetes [11].

2. History of T2DM and the burden of the disease
Diabetes, in all likelihood, has been recognized as a dangerous
metabolic disorder long before it was first mentioned in the
Ebers papyrus that provides a comprehensive list of diseases
known during the 18th Egyptian dynasty (c. 1630–1350BCE).
Descriptions of diabetes have been found in ancient Indian and
Chinese medical literature, as well as in the work of ancient
Greek and Arab physicians, and in the works of Avicenna (9801037), who also described complications like sexual dysfunction
and gangrene [12-14]. Diabetes was known under different
names including the “pissing evil” in the 17th century. The term
“diabetes” was probably coined by Apollonius of Memphis
around 250 BC from Greek origin meaning “go or pass through.”

Figure 1. T2DM is a complex multisystem disease comprising numerous metabolic defects that contribute to the development of hyperglycemia.
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Diabetes is first recorded in English, in the form “diabete,” in a
medical text written around 1425. The English anatomist and
physician Thomas Willis (1621-1675) is attributed with adding
Latin “mellitus (honey-like, sweet) to Greek “diabetes”–siphon,
to pass through—to better reflect one of the major diagnostic
parameters of the condition—excessive sugar in urine [14].
T2DM is a complex multisystem disease comprising
numerous metabolic defects that contribute to the development
of hyperglycemia (Figure 1). Insulin resistance (IR) in the skeletal
muscle and liver along with progressive pancreatic β-cell
degradation are considered the main causes for the development
and progression of hyperglycemia. However, research in the
mechanisms of glucose disequilibrium unveiled a very complex
network of organ and tissue interaction. Dysfunctions in the
gastrointestinal tract, endothelium, adipose tissue, pancreatic
alpha cells, brain, and kidneys have been described, and,
together with insights into the involvement of liver, muscle, and
β-cells produce a robust picture of T2DM pathology (Figure 1).
There is a growing understanding of oxidative stress playing
an important role in the pathogenesis of IR, dyslipidemia and
metabolic syndrome [15]. As pathophysiologic mechanisms and
defects continue to be discovered, they offer an expansion of
potential targets for treatment of T2DM [16].
The specific courses of T2DM development remain unknown
even though associated risk factors and overall pathogenesis
have been described at length. IR, decreased sensitivity to
circulating insulin,is the defining key pathology that triggers
compensatory hyperinsulinemia and when pancreatic β-cell
capacity is insufficient to maintain glucose homeostasis, leads to
the development of T2DM. β-cell failure, along with IR in muscle
and the liver, represents the core pathophysiologic defects in
T2DM. A number of pathophysiological abnormalities linked
to IR development were added to diabetes pathophysiology to
reflect the complex nature of hyperglycemia (Figure 1). Multiple
factors are directly linked both to the onset of diabetes and its
progression, and are targets for T2DM treatment and prevention.
Recent progress in describing the molecular mechanisms of IR
significantly improved our understanding of pathways of T2DM
onset and progression [17].
3. Etiology of T2DM
IR is a primary factor in hyperglycemia a key symptom of T2DM.
Even though the exact causes for the development of T2DM are still
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not very clear, several important risk factors have been identified.
A combination of inherited, behavioral and environmental
factors leads to metabolic syndrome and eventually to the T2DM
onset. Among the key factors are excess body weight, physical
inactivity and poor nutrition. Ethnicity, family history of diabetes
(genetics), past history of gestational diabetes, birth weight,
certain medications, smoking and advancing age also play an
important role [18]. The identification of novel biologic predictors
for T2DM and IR may help improve risk assessment and unveil
causal pathways beyond established genetic and lifestylerelated factors. Recent advances have made large-scale -omics
studies possible that have pinpointed several tentative novel
biomarkers for T2DM, including branched-chain amino acids and
circulating micro RNAs, Molecular mechanisms of IR are being
studied at length [19-22]. It has been shown that p53 has the
capacity to control the expression of metabolism-related genes
that are important regulators of metabolic pathways, including
glycolysis, oxidative phosphorylation, fatty acid metabolism and
mTOR signaling [23]. Intensive research in biomarkers for IR
has suggested several target candidates, including adiponectin,
retinol-binding protein-4 (RBP4), chemerin, adipocyte fatty acidbinding protein, fibroblast growth factor (FGF21), fetuin-A,
myostatin, interleukin (IL-6), irisin, and ghrelin, all of which
may play a significant role in determining insulin sensitivity [2426]. The elevation in baseline serum uric acid was found to be
an independent risk factor for gout, hypertension and both IR
and T2DM [27]. Further, a recent meta-analysis demonstrated
an association of low-density lipoprotein cholesterol (LDL-C)lowering genetic variants in or near Niemann-Pick C1-Like
1( NPC1L1) and some other genes with a higher risk of T2DM
[28]. In addition, among the Apolipoprotein A-V (APOA5) gene
SNPs, the C allele of -1131T>C polymorphism is a risk factor for
metabolic syndrome [29]. However, it is not clear yet what could
be gained from adding novel circulating biomarkers and genetic
markers to traditional T2DM risk factors.
4. T2DM as systemic disease
4.1. Muscles
In muscles, IR is manifested by impaired glucose uptake
following ingestion of a carbohydrate meal and results in
postprandial hyperglycemia. The signal transduction cascade
from insulin receptors to glucose transporter type 4 (GLUT4),
which ultimately is responsible for insulin-stimulated muscle
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glucose uptake, is well understood and includes insulin receptor
substrate (IRS1) and phosphatidylinositide 3-kinases (PI3K)/
Akt signaling pathway [30, 31]. Elements of this cascade are
linked to AMP-activated protein kinase (AMPK), glycogen
synthase kinase-3 (GSK3), and mammalian target of rapamycin
(mTOR) pathways that play an important role in cell energy
metabolism [32]. GLUT4 is in the center of glucose uptake by
skeletal muscles and T2DM is linked to GLUT4 dysfunction or
reduction in GLUT4 gene expression. IR is strongly associated
with increased intramyocellular lipid content and inflammation.
However, specific molecular mechanisms responsible for IR
onset are still obscure. Molecular mechanisms of the IR include
a variety of possible pathways interfering with insulin-GLUT4
signal transduction cascade. One of the best studied is a lipidmediated (e.g., diacylglycerols, fatty acids) the IR [22, 33, 34].
4.2. Liver
The liver plays an essential role in glucose metabolism. In
a normal state, the combination of hyperinsulinemia and
hyperglycemia maximizes net hepatic glycogen synthesis. In the
liver, IR is manifested by an overproduction of glucose during
the basal state despite the presence of fasting hyperinsulinemia
in response to insulin, following a meal. Insulin is a central
regulator of the postprandial transition of hepatic glucose
metabolism from glucose production to glucose storage. Hepatic
insulin action requires a coordinated relay of intracellular signals
and includes both direct and indirect mechanisms [22, 35]. It
was demonstrated that diacylglycerol (DAG)-mediated activation
of protein kinase C (PKC)ε impairs hepatic insulin signaling,
reduces hepatic glycogen synthesis and strongly correlates with
increased glucose production [36]. In addition, substrate flux
manifested as additional glucose diverted to the liver due to
muscle IR, leading to de novo lipogenesis and hyperlipidemia
and FAs being released in adipose lipolysis in white adipose
tissues, further drive hepatic lipid synthesis and activates hepatic
gluconeogenesis Acetyl-CoA–mediated activation of pyruvate
carboxylase, increasing glucose production [22, 37].
4.3. Pancreas
4.3.1. Pancreatic β-cells
IR places a major stress on pancreatic β-cells to enhance their
secretion of insulin to offset the reduction in insulin action.
Provided β-cells are able to increase their secretion of insulin
204
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sufficiently to counter balance IR, glucose tolerance remains
normal. However, gradually, the β-cells begin to fail and initially
the postprandial plasma glucose levels and subsequently, the
fasting plasma glucose concentration begins to rise, leading to
the onset of overt diabetes [38]. Impairments in β-cell mass and
in insulin secretion have been reported in numerous studies in
patients with T2DM [39]. There is a tight relationship between
the mass of pancreatic β-cells and functional insulin secretion.
The onset and pace of β-cells failure determine the rate of
progression of hyperglycemia. A variable combination of loss
of mass and loss of function appears in T2DM [39]. The β-cells
mass remains constant during adulthood, indicating that β-cell
turnover is limited in humans. Recent studies have suggested
that there is an increase in β-cell neogenesis in humans with
obesity, pregnancy and impaired glucose tolerance; however, the
extent of its contribution to β-cell mass remains unclear [40].
By the time a diagnosis of diabetes is made, the patient has
lost over 80% of his/her β-cell function, and it is essential that
the physician intervenes aggressively with therapies known to
correct pathophysiological disturbances in β-cell function [41].
4.3.2. Pancreatic α-cell.
In T2DM subjects, dysregulation of the pancreatic α-cell activity,
linked to abnormal sensitivity to glucose with less suppression
during hyperglycemia, leads to the elevated basal plasma
glucagon concentration and in the increased basal rate of
hepatic glucose production [41]. Thus, in diabetic subjects with
persistent fasting hyperglucagonemia, postprandial hepatic
glucose production remains elevated at fasting levels rather than
making the rapid postprandial decline typical of nondiabetic
subjects. Glucagon excess, rather than insulin deficiency, may be
essential for the development of diabetes. Suppressing glucagon
action should effectively decrease the long-term complications
and metabolic derangements of diabetes, enhancing the
quality of life of diabetic individuals [42]. Glucagon is the
chief secretory product of α-cells and has been the principle
measure of α-cell function. Dysregulated glucagon secretion
plays an important role in the pathogenesis of T2DM. Glucagon
secretion is normally downregulated by high glucose levels,
insulin, amylin, somatostatin and glucagon-like peptide 1 (GLP1) [43]. Physiological effects of glucagon are defined by its
hypoglycemic counter regulation and include increased hepatic
glucose production, reduction of glucose oxidation and rapid
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mobilization of stored glucose for export to the circulation. Also,
glucagon mediates the enhanced rates of hepatic lipid oxidation
characteristic of fasting, effects that were due to G-proteincoupled glucagon receptor activation of peroxisome proliferatoractivated receptor alpha (PPARα) and p38MAPK signaling to
increase the expression of enzymes involved in β-oxidation
[44]. Accelerating lipid oxidation provides energy for glucose
anabolism. It is well-established that in states of poorly controlled
diabetes with severe insulin deficiency or ketoacidosis, plasma
glucagon concentrations are extremely high and that failure to
suppress fasting levels of glucagon after eating contributes to
hyperglycemia [45, 46]. With clinical studies underway, it has
become apparent that suppression of glucagon secretion or
antagonization of the glucagon receptor constitutes potentially
effective treatment strategies for patients with T2DM [43, 47].
4.4. Gastrointestinal tract
The incretin effect refers to a well-established fact that glucose
administered orally elicits a significantly greater insulin response
compared to an intravenous glucose infusion. The join action
of two insulinotropic intestinal peptides, glucagon-like peptide
(GLP-1) and gastric inhibitory polypeptide (GIP), is responsible
for the incretin effect and a decrease in blood glucose levels
[48]. The gut hormones, GLP-1 and GIP, secreted respectively
from the intestinal L-cells and K-cells, account for up to 70%
of insulin secretory responses after nutrient ingestion [49].
In addition, GLP-1 is known to be a physiological inhibitor of
glucagon secretion, while GIP can stimulate glucagon secretion
[50]. Growing evidence suggests that GLP-1 promotes fatty acid
oxidation, reduces lipogenesis in the liver and may increase
hepatic glucose uptake [51, 52]. Furthermore, the postprandial
release of GLP-1 might alter reward processes in the orbitofrontal
cortex, thus exerting satiety effects [53].
4.4.1. Gut microbiome
A rapidly mounting body of evidence shows that gut microbiota
plays an important role in the development of IR [54]. Recent
microbiota transplantation studies from insulin resistant donors
to germ-free animals indicate the causal effect of microbiota [55,
56]. There is an intensive biochemical and immune “crosstalk”
between gut microbiota and the host [57, 58]. On the one
hand, gut microbiota may contribute to host IR in various ways,
including host appetite, energy balance, fat storage, low-grade
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inflammation etc, [59]. On the other hand, the genetics and
health condition of the host can shape gut microbiota [56, 60].
Human genes, microbial genes, and diet share a complicated set
of interdependencies [61, 62]. The gut microbiome may be an
important target for the management of T2DM [63].
4.5. Kidneys
Our understanding of T2DM has been enhanced significantly
by recognition of the role of kidney glucose transporters in
regulating plasma glucose levels and producing hyperglycemia.
In individuals with normal glucose tolerance and a mean day
long plasma glucose concentration of 100 mg/dl, all glucose
is reabsorbed via sodium–glucose cotransporters SGLT1 and
SGLT2 located in proximal tubule; hence no glucose is excreted
in the urine [64]. While the SGLT2 is strictly localized in kidneys,
the SGLT1 also is expressed in the gut, heart and lungs [64]. In
healthy individuals, glucosuria may start at the plasma glucose
levels of 180 mg/dl. Kidney adaptive reaction to a high level of
glucose in the glomerulus is to conserve glucose by increasing
glucose reabsorption through upregulation of SGLT2 expression
and increased glucose transport capacity in T2DM subjects. This
contributes to persistent hyperglycemia. The maximum glucose
transport capacity (Tm ) of the proximal tubule on average is 375
mg/min, which roughly corresponds to 300 mg/dl plasma glucose
level. In T2DM subjects, all of the filtered glucose in excess of the
Tm is excreted in the urine [64-66]. Because sodium and glucose
are cotransported in renal proximal tubular cells, T2DM subjects
have an increase in total body sodium content and a high risk
of hypertension [67]. Inhibition of SGLT-2, which is responsible
for approximately 90% of renal glucose reabsorption,
increases urinary glucose excretion and lowers blood glucose
concentrations. SGLT-2 inhibitors improve glycemic control,
reduce body weight and blood pressure, and are associated
with a low risk of hypoglycemia [68]. In clinical trials, an SGLT2
inhibitor (empagliflozin) was found to have a profound effect
in reducing cardiovascular and all-cause mortality in patients
with T2DM and antecedents of cardiovascular disease [67]. This
effect, however, was attributed mostly to a hemodynamic rather
than a metabolic effect in part due to osmotic/diuretic effect
of the SGLT2 and to the reduction in arterial blood pressure.
Adverse events associated with SGLT-2 inhibitors include mild
to moderate urinary tract and genital infections and mild
dehydration, potentially leading to orthostatic hypotension [69].
www.cajms.mn
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4.6. Brain
The brain is an insulin-sensitive organ [70]. Insulin can cross the
blood-brain barrier and the insulin receptor β is highly expressed in
neurons in different brain regions [71]. Significant changes occur
in the brain signaling systems regulated by insulin, insulin-like
growth factor (IGF-1), leptin, dopamine, serotonin, melanocortins
and GLP-1 even at the early stages of T2DM [72]. Also, there is
a growing understanding of the role that the low-density lipoprotein
receptor-related protein 1 (LRP1) may play in the regulation of insulin
signaling and glucose metabolism [73]. Insulin also acts on the
brain, which independently suppresses lipolysis by suppression of
sympathetic outflow and increases triglyceride secretion from the
liver through yet unknown mechanism [37].The brain is implicated
in T2DM onset and pathology through a neuroendocrine network of
appetite suppression and regulation of numerous metabolic processes
[74]. The absolute majority of obese subjects either developed
or have a very high risk of developing T2DM [75]. It is known
that obesity results in the brain becoming resistant to a number
of satiety-inducing hormones, including insulin and leptin [7677]. Both insulin and GLP-1 decrease activity in the orbitofrontal
cortex and synergistically contribute to the regulation of regional
brain activity in the postprandial state [53]. Insulin regulates
activity within many eating behavior-relevant regions, including
areas of occipital and prefrontal cortical regions, hypothalamus,
midbrain, brainstem, and regions within the striatum [76]. In
addition, insulin modulates cognition, body weight, wholebody glucose, energy, and lipid metabolism [70, 78]. Metabolic
abnormalities that characterize insulin-resistance syndrome
may be at least partially associated with modulation of central
melanocortinergic neurons that have a major impact on visceral
adiposity and peripheral and hepatic insulin actions [79]. It is
recognized that the functional state of the brain-signaling
systems plays an important role in etiology and pathogenesis
of T2DM and metabolic syndrome (MS). The pharmacological
approaches controlling the brain-signaling systems regulated by
insulin, IGF-1, leptin, dopamine, serotonin, melanocortins and
GLP-1can be regarded as a promising way to treat and prevent
these diseases and their complications [72].
4.7. Adipose tissue
It widely recognized that adipose tissue, in addition to being a
primary storage of energy, plays a very important role in body
metabolism primarily through adipocyte-macrophage interaction,
206
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releasing adiponectin, FA and the hormone leptin [80-82]. With
only about 10% total systemic glucose uptake, adipose tissue
may play only a minor quantitative role in postprandial glucose
metabolism. On the other hand, growing evidence implicates
unbalanced adipocyte metabolism and altered fat topography
in the pathogenesis of glucose intolerance in T2DM [83]. Insulin
suppresses adipose lipolysis hence reducing glycerol delivery to
the liver and also lowering hepatic Acetyl-CoA content. Insulin
also regulates basal lipoprotein lipase expression and activity of
a number of other proteins [35, 37, 84]. Visceral fat deposition is
the seminal factor that ultimately causes IR and the detrimental
inflammatory and hormonal profile that contributes to increased
risk for cardiovascular disease. Adipocyte hypertrophy and
other poorly understood factors set off a pathologic adipocytemacrophage crosstalk (Cusi 2010) resulting in adipocyte IR
and the chronic release of FFA with toxic effects (lipotoxicity)
in distant tissues such as muscle, liver, and pancreatic β-cells
as well as on the heart and vascular bed [37, 85, 86]. However,
10% to 45% of the adult obese population is represented by
the metabolically healthy obese individuals who possess a
unique subset of characteristics that reduce metabolic and
cardiovascular risk factors despite the presence of excessive fat
mass [75].
4.8. Endothelium: macro- and microvascular
complications
In healthy individuals, the endothelium regulates a complex
balance of factors that maintain vascular homeostasis and
normal arterial functions, including cellular adhesion and vessel
wall inflammation in addition to maintaining vasculogenesis,
and angiogenesis [87]. Changes in endothelium functions are
implicated in microvascular complications, such as retinopathy,
neuropathy and nephropathy. A shift in the functions of the
endothelium towards vasoconstriction, proinflammatory and
prothrombic states characterizes the disruption of the normal
performance of endothelial cells, leading to endothelial
dysfunction, which is implicated in the pathogenesis of many
diseases including diabetes [88]. The last three decades of
the Steno hypothesis development and recent discoveries in
the field advanced deep understanding of the pathogenesis,
manifestations and sequelae of global dysfunction of the vascular
endothelium in diabetes mellitus [89, 90]. The hyperglycemia
condition of endothelial cells, by inducing elevation of DAG,
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activates PKC pathway resulting in increased oxidative stress
[15, 88]. A complex array of factors is associated with the
pathogenesis of endothelial dysfunction [87]. Even that causality
may be not very well established; multiple pathways leading to
microvasculopathy, have been characterized. They include the
endothelial nitric oxide synthase (eNOS) uncoupling and NO
deficiency, oxidative and nitrosative stress, lysosomal membrane
permeabilization and sirtuin 1 (SIRT1) deficiency, increased
production of inﬂammatory factors, abnormal angiogenesis,
premature senescence of endothelial and endothelial progenitor
cells, and disintegration of endothelial glycocalyx have been
characterized [90]. There is growing interest in the modulatory
role of microRNAs in diabetes-induced vascular dysfunction
[87, 90]. A combination of systemic inflammation and the
presence of high blood glucose concentrations is able to impair
the vascular endothelium in its function, thus predisposing
one to atherosclerotic disease. The enhanced oxidative stress,
the increased circulating free fatty acids and the altered lipids
metabolism induce heart structure damages that can also lead
to diabetic cardiomyopathy [15, 91].
5. Contemporary treatment options for T2DM
There is an intense focus on the evidence base for optimal T2DM
management with the ability to deliver effective multidisciplinary
care after early diagnosis and initiate effective glucoselowering therapies supported by structured education and selfmanagement programs [92].The European Association for the
Study of Diabetes and American Diabetes Association adopted a
patient-centered approach that includes optimizing therapeutic
options across the life span - the Chronic Care Model (CCM)
for prevention and treatment of T2DM. A major barrier to
optimal care is a delivery system that is often fragmented,
lacks clinical information capabilities, duplicates services, and is
poorly designed for the coordinated delivery of chronic care
[93]. The CCM has been recognized as an effective framework
for improving the quality of diabetes care, emphasizing the
roles of the health care delivery team and promoting selfmanagement on the part of the patient [93]. Lifestyle
changes, which may include setting physical activity and weight
loss goals, remain the initial intervention for T2DM and Medical
Nutrition Therapy has become an integral component of
T2DM prevention, management, and self-management
education [94]. First-line therapy, involving metformin along
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with lifestyle modification (diet, exercise, and weight loss), is
typically low cost. However, many patients fail to meet glycemic
targets on this regimen and require treatment intensification
[95]. Current glycemic recommendations recognize A1C 7.0%
(53 mmol/mol), preprandial capillary plasma glucose 80–130
mg/dL (4.4–7.2 mmol/L), and peak postprandial capillary plasma
glucose,180 mg/dL (10.0 mmol/L) for nonpregnant adults with
diabetes.
5.1. Pharmacological therapy for T2DM
Although prevention of T2DM is the ideal solution and has been
shown to be cost-effective in modeling studies, providing optimal
cost-effective treatment to those with T2DM is an urgent medical
need [95]. Given that the high costs of managing T2DM are
driven in large measure by complications that are a consequence
of poor glycemic control, the goal for T2DM patients is to attain
and maintain glycemic control. Research shows that intensive
blood glucose control can reduce the risk of T2DM complications
and the cost of managing these complications over periods from
10 years to a lifetime [95].The current approach to management
of T2DM is based on the escalation of intervention based on
patient response and success in glycemic control. In a recent
meta-analysis, it was found that among adults with T2DM, there
were no significant differences in the associations between any
of nine available classes of glucose-lowering drugs (alone or in
combination) and the risk of cardiovascular or all-cause mortality.
Metformin was associated with lower or no significant difference
in HbA1C levels compared with any other drug classes. All
drugs were estimated to be effective when added to metformin
[96]. Hence, metformin, if not contraindicated and if tolerated,
remains the preferred initial pharmacological agent for T2DM
[93, 96, 97]. However, if noninsulin monotherapy at maximum
tolerated dose does not achieve or maintain the HbA1C target
over three months, dual and triple therapy may be used with
combinational injectable insulin therapy considered when blood
glucose is 300–350 mg/dL (16.7–19.4mmol/L) and/or HbA1C
is10–12% (86–108 mmol/mol) [93]. The pharmacological and
therapeutic implications of current drugs for T2DM were recently
extensively reviewed [98, 99].
5.2. The need for new therapeutic agents
A recent study demonstrated that among adults with type 2
diabetes diagnosed for less than 10 years, a lifestyle intervention
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compared with standard care had only limited success and
resulted in a change in glycemic control that did not reach
the criterion for equivalence [100]. New technologies and
therapeutic options for T2DM patients are being extensively
investigated [92]. Well-tolerated treatments that produce
a long-lasting impact on IR are in great demand. Owing
to better understanding of the pathogenesis of IR and the
network of the insulin signaling pathway, as described above,
several pharmacological agents have been developed to treat
IR. Currently available treatments such as biguanides and
thiazolidinedione are effective, but their impact may not be
sustained and they have considerable adverse event profiles.
Many treatments in development, which target different aspects
of the insulin-signaling pathway, did not progress beyond
preclinical development; others that reached clinical trials had
significant adverse events and/or modest efficacy. In addition,
the treatments must be specific and reversible, as many of the
components of the insulin-signaling pathway are involved in
other cellular functions, such as apoptosis. Despite their efficacy
in treating IR, lifestyle interventions have not been embraced by
patients and bariatric surgery has become quite common as a
treatment option for patients with obesity [101]. There is a great
need for developing a cluster of new therapeutic agents that will
provide safe and sustainable improvement in IR and/or prevent
comorbidities associated with T2DM. Multicomponent botanical
therapeutics may play an important role in developing this type
of agents.
6. An approach to utilize Avicenna’s heritage in the
modern world.
Avicenna remains one of the highest medical authorities for the
Central Asian population. His philosophy, including a general
approach to human health and healing, has a profound effect on
practicing medicine by traditional healers and medical doctors
alike. There are two major, sometimes interrelated, approaches
for utilizing Avicenna’s heritage: practicing the traditional Unani
system of medicine and developing novel therapeutic agents.
The Unani system of traditional medicine has been used for
centuries and even though some of the practice success may be
attributed to a placebo effect, it remains an important part of
the health care system, particularly in rural areas of Afghanistan,
Pakistan, India, Tajikistan, Mongolia, Uzbekistan, and other
Central Asian countries. On the other hand, incorporating
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evidence-based healing approaches into contemporary medical
and pharmacological practices is a comprehensive multifaceted
process [102]. This process requires an in-depth understanding of
philosophy and evidence-based medicine practiced by Avicenna.
Interpretation of the ancient Arabic text is a challenging
problem and requires a combination of remarkable language
skills, understanding of medieval medical practices and broad
knowledge of modern science. One of the coauthors of a current
paper (Yusuf Nuraliev) is a practicing physician and clinical
pharmacologist and is also fluent in Arabic. He served as a
scientific consultant for the latest translation of Avicenna’s books
to Russian (Dushanbe 2005 – 2015). In the course of his reading
“The Canon of Medicine”, he noticed that previous Russian
translations of chapters devoted to diabetes recommended
using “laxative remedies” that very much contradict the general
understanding of disease progression and symptoms both from
Avicenna’s and modern points of views. Further analysis unveiled
that the Arabic phrase “cleansing “wujud” (existence or inside)
was interpreted as “laxative effect” or “laxative remedy.” Indeed,
the phrase should be interpreted as cleansing the “inside” of
the organism and, most likely, could be linked to repairing the
function of the endothelium [3] (Figure 1). The difficulties of
translation and interpretation are particularly acute through the
chapters devoted to chronic diseases and disorders including
diabetes. It is not surprising that Avicenna’s writing is still full
of undiscovered secrets. It is necessary to combine any recent
scientific research on Avicenna pharmacology, identification of
medicinal plants and method of preparation. Some of the herbal
preparations have been used for a long time and a have good
safety record. It is possible to streamline botanical therapeutics
leads identification and pharmaceutical development by effective
use Avicenna’s heritage. In addition, complex medieval botanical
preparations and individual medicinal plants can be tested
against multiple new targets identified by modern science. Those
botanicals can be effectively incorporated in different steps of
the contemporary drug development process, including discovery
and development, preclinical and clinical research, regulatory
approval and post-market monitoring.
7. Role of medicinal plants in diabetes treatment and
prevention
Though there are various pharmaceuticals available for
prevention of metabolic syndrome and treatment of diabetes,
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herbal formulations are often preferred due to low cost, fewer
side effects and longer shelf life [103]. This trend is especially
visible in countries with populations with a limited income
and well-established practice of traditional medicine such as
Tajikistan, India, Iran, Saudi Arabia, China and others [104-108].
There are attempts to validate the traditional use of medicinal
plants using contemporary scientific methods [109-111].
Multiple plant species used in traditional medicine in different
parts of the world have been shown to have at least some
antidiabetic activity [112]. A considerable number of plants was
subjected to clinical trials and found effective. Moreover, during
the past few years, many bioactive phytochemicals have been
isolated from hypoglycemic plants [113, 114].
Multiple mode of actions were suggested for antidiabetic
medicinal plants. For example, antidiabetic actions of cocoa
flavanols might contribute to prevention or delay in T2DM onset
by modulating insulin secretion in pancreatic cells and targeting
insulin-sensitive tissues because of their insulin-like activity or
through the regulation of key proteins of the insulin-signaling
pathways. Cocoa flavanols have been proved to enhance glucose
uptake through the promotion of glucose transport, to repress
glucose production, or to improve lipid metabolism [115]. Thirtyfive plant species traditionally used by the indigenous peoples
of the boreal forest in Canada for three or more symptoms of
diabetes or its complications demonstrated high free-radical
scavenging activity [116]. Grape polyphenols protect against
metabolic syndrome by acting in the intestine to modify gut
microbial community structure, resulting in lower intestinal and
systemic inflammation and improved metabolic outcomes [63].
8. Unani system of medicine practiced by Avicenna
In the Unani system of medicine, practiced by Avicenna, a
physician (healer) initially determined features of “mizaj” of a
healthy person, then its changes in diseases, as well as “mizaj”
of medicines, which are prescribed to correct the disease
“mizaj.” The mizaj was often translated as a “temperament”
or sometimes as “nature” [3]. The person’s mizaj consists of
the balanced interaction of the four conflicting principal forces/
qualities (hotness, coldness, dryness and moisture) within the
elements (earth, air, water, fire) [2, 117, 118]. There are four
humors (also translated as “fuel” or “juices”) in the body:
blood (dam); phlegm (balgham); yellow bile (safra); and black
bile (sauda), each of which is associated with a pair of qualities:
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hot and moist, cold and moist, hot and dry, and cold and dry,
respectively. These humors form sanguineous, phlegmatic
(serous), bilious (red bile), and melancholic (atrabilious) (black
bile) humors (akhlat) in the body. Each individual has a dominant
and subdominant temperament with all these humors existing in
each individual’s body.
The mizaj of a healthy person is considered as «motadil»
- neutral or calm when all four properties of hotness, coldness,
dryness and moisture are in harmony and proportional quantity
inherent to a particular individual or organ. “Sue mizaj” or
dystemperament is the deficiency and decrease in the physiologic
action and reaction of the body, in a way that disturbance and
dullness happen in its chemical action. Avicenna described 16
distinct types of disorders of temperament (called by names
such as sue mizaj, inequable temperament, intemperament,
dyscrasias), which cause sue mizaj gheiremotadil, or imbalance
in the body.
Treatment is aimed directly at restoring balance or
equilibrium of various elements, humors and faculties to the
patient’s temperament or humors. Individualized treatment relies
on the psychophysiological physique of the patient. Avicenna
states, “Truly, when the quality of the disease is understood,
it is necessary to choose a medicine with the opposite quality,
for the disease is treated with opposition”[118]. The physician’s
task was to restore the balance of disturbed mizaj to the level
of «motadil», i.e. “balanced nature” by means of suitable
medications. A single drug should not be used to treat one and
the same disease. Indeed, Avicenna warned that when treating
diabetes, one should not take the same medicine with long (and
repeated courses) treatment. The treatment must include the
six factors to ensure that, not only are the symptoms treated,
but the causes of illnesses are also focused upon. While modern
medicine often aims at controlling symptoms and managing
illnesses, the Unani system of medicine aims at curing illnesses
and managing health [117]. Different ideas about treatment, or
ilaj, introduced in traditional medicine, are grouped asilaj-bilTadbeer (regimental therapy), Ilaj-bil-Ghiza (dietotherapy), IlajbilDawa (pharmacotherapy) andIlaj-bil-Yad (surgery) [117].
9. Methods of diabetes treatment used by Avicenna
Ethnobotanical studies in Central Asia report that the local
population still broadly uses medicinal plants in treating T2DM
[119]. Many modern folk healers and even physicians, involved
www.cajms.mn
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in the treatment of diabetes, keep secret the remedies and
therapy methods used for the management of the disease. If
asked what they use to treat diabetes, the healers usually do not
provide direct answers or just say that they use techniques of
Avicenna or other well-known ancient authorities.
For the purpose of this article, we mostly concentrated on
the materials from“The Canon of Medicine” and the treatise AlVohiya or Faiziya (from the Arabic word”vohiya”orcode and from
the Tajik word “faiziya” or good) —”Code of Recipes” or “Useful
Recipes.” The latter work presents a kind of pharmacotherapeutic
guide for the use of simple medicines, depending on the character
of their therapeutic effect manifestations in the treatment
of certain diseases [4, 120]. Avicenna used in “The Canon of
Medicine” techniques and methods based on advances in the
scientific and medical terminology of his era. He describes
cleansing, cooling, decontamination therapy and treatment with
the principles of “opposite with opposite” and “like with like.”
Several hundred substances and receipts from different sources
are mentioned for treatment of different illnesses in the Canon
[121]. Avicenna described the condition of plant collection and
storage, which guaranteed the quality of primary materials [122].
Thus far, most medicinal substances prescribed by Avicenna
remain largely unexamined. When prescribing individual herbal
remedies, Avicenna often gave only the name of the medicinal
herb, or the therapeutic form. In some cases, he provided a very
short description, for example, prescribing the powder from the
leaves or dried fruits of a particular plant, or from roots of a
certain tree in a dose of 0.5 or more dirhams, so many times per
day. A physician unfamiliar with the basics of ancient medical
terminology does not know how many grams or milligrams
correspond to 0.5 dirham (about 1.5 gram). In Avicenna’s
literary works, many recipes provide only the generic name of
the plant, such as powder from the leaves of mint or oregano.
However, each of these plants includes multiple varieties
growing in various geobotanical areas on different continents.
Given these obstacles, only a trained professional can accurately
select the desired plant species. The medieval medico-biological
terminology associated with the teaching of mizaj, mizajdiagnostics and mizaj-therapy present additional challenges for
interpreting Avicenna’s approach to treating various diseases.
Anin-depth analysis of Avicenna’s writings reveals that he
considered that, in diabetes, the character of mizaj changes to the
“cold” side. In modern understanding, this may refer to a shift of
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pH of the body fluids towards acidosis. Under the influence of the
products with the “cold nature,” according to Avicenna, there is
a significant change of the mizaj of internal environment to the
cold, i.e. acidic direction, primary in endothelium, as well as in
the kidneys and liver, leading to diabetes. Avicenna often defined
character mizaj of drugs by their organoleptic and physical
parameters, such as taste, smell, color and consistency. In the
treatment of patients, he demonstrated a very rigorous approach
to determining the character of the mizaj of the human body as
a whole, the character of changes of the patient’s body mizaj,
as well as the character of the mizaj of prescribed medicines.
In accordance with the classification in the Unani system of
medicine, most remedies have a simple nature: hot, cold, dry
or wet. Combinations of these properties define complex mizaj.
Avicenna describes two different tactics in treating
patients: “like with like” and “opposite with opposite” [118].
According to Avicenna, the therapy tactics “like with like,”i.e.
treatment of cold acidosis by means of cold acidic agents was
unacceptable, as it promoted deterioration of the patient [123].
Consequently, Avicenna prohibited the prescribing of acidic
foods and beverages in diabetes, realizing that these foods
aggravate the shift of patient mizaj to the cold diabetogenic
side [124]. The therapy tactics “opposite with opposite,”i.e.
treatment of acidosis status by using alkalizing agents, is the
basis of diabetes therapy by Avicenna. In the basis of Avicenna’s
medicinal remedies intended for pathogenic and adjuvant
(accessory) therapy of different degrees and forms of diabetes
were vegetables, minerals and animal products with alkalizing
properties, which fully corresponds to the therapy tactics
“opposite with opposite”[125].
Avicenna emphasized that mizaj is an inherent property of
the person and the knowledge of the characteristics of mizaj
allows to correct its deviations occurring in various diseases
and to restore health [4]. By Avicenna’s definition, “health
preservation is achieved by balancing (using) certain things and
avoiding others. The balance of that what should be withdrawn
from the body and that what should be held in it. Avoid that
what generates fatal, bad nature, hot or cold, and that what is
opposed to the nature (of human) by its special property”[118].
Avicenna identified diabetes in “The Canon of Medicine”
as an independent disease, having a connection with diseases
of the kidneys and the liver and the pollution of all liquids of
the internal environment of the organism, i.e., “wujud.” We
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believe that in modern medicine, an understanding of wujud is
consistent with the endothelium, which is recognized today as
the largest endocrine organ in the body [90].
9.1. Evaluation of the antidiabetic treatments proposed
by Avicenna
In evaluating Avicenna’s treatment of diabetes, researchers at
the Institute of Avicenna’s Medicine and Pharmacology (IAMP,
Dushanbe, Tajikistan) have concentrated on two primary
characteristics of medicines: the cold mizaj corresponding to
the manifestation of acidity and hot mizaj corresponding to
alkalinity. A comprehensive approach is used in an analysis of
Avicenna’s treatment and prevention of diabetes. To identify
plants, minerals and animal products suggested by Avicenna for
diabetes treatment and prevention multiple sources, including
publications in English, Russian, Tajik and Arabic languages were
cross-referenced. Every treatment, which is aimed at correcting
the violated mizaj, in general can be called mizaj-therapy,
i.e. the predecessor of the modern pathogenical therapy in
pharmacology.
As described above, there are many etiological factors
contributing to the origin of pre-diabetes and IR, and they often
are not interrelated. Among those factors, the manifestation of
acidic properties, eventually contributing to the onset of prediabetes and IR, could be a common trigger [120]. Avicenna
considered that the sour taste inherent in plants and food
products is the main indicator of the cold mizaj. He noted that
the consumption of sour (acidic) foods causes a change of mizaj
of the human body to the cold (sour, acidic) i.e. diabetogenic
side.
A growing pool of evidence suggests that a diet with high
acid load increases body acidity and may be an independent
predictor of developing IR and T2DM [126]. Higher acidic
dietary acid-base load, defined by higher the potential renal
acid load and net endogenous acid production scores, may
be an independent risk factor for the development of IR and
related metabolic disorders [127, 128]. Mild metabolic acidosis,
measured by plasma lactate, aligns with insulin resistance
independent of obesity and is induced by short-term increases
in energy and dietary acid load in healthy humans [129]. In large
prospective cohort studies, a high dietary acid load was positively
associated with T2DM risk and found to be independent of other
known risk factors for diabetes [130-132]. Meta-analysis of the
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three prospective cohort studies further confirmed that, after
adjustment for other diabetes risk factors, a higher dietary acid
load is associated with an increased risk of T2DM [133].
In our experiments, supplementation of the diet with a
daily gavage of 5 ml/kg fresh lemon juice in rabbits for two
weeks resulted in changes associated with diabetogenesis.
Blood and urine pH was reduced 6.2% and 16.9% respectively,
and the glucose level in blood increased 58.1% and HbA1c
increased 72.3%. In addition to mild acidosis, physiological
and biochemical changes showed the development of IR and
associated modifications of liver and kidney functions [124]. We
also showed that six acidic products included in the diabetogenic
risk factors by Avicenna have pharmacological and biochemical
effects on the organism of laboratory animals consistent with
the development of diabetes [6].
Following his predecessors, Avicenna considered that thirst
and polyuria are the main symptoms of diabetes, and noted,
“in the urine of patients with diabetes a substance resembling
honey to taste.” Antidiabetic agents, which have been used
during that historical period, mainly were evaluated according
to the manifestation of their thirst-quenching effect [134, 135].
Pharmacological and biochemical screening conducted at IAMP
showed that medicinal plants recommended by Avicenna have
not only thirst-quenching action but also a hypoglycemic effect
(data not shown). This relationship is also noted by modern
studies [136].
In the opinion of Avicenna, all dysmetabolic processes in
diabetes are the result of dysfunctions in the three main organs:
the endothelium, kidneys and liver. In his doctrine, Avicenna pays
special attention to developing common drug therapy tactics for
diabetes, especially onIlaj-bil-Ghiza (dietotherapy). Developed by
Avicenna the tactic of diabetes therapy encompassed all major
pathogenic disturbances observed in the kidneys, liver and
endothelium in the early stages of the disease, i.e. it is focused
entirely on the elimination of the state of pre-diabetes.
As an experienced physician practicing evidence-based
medicine, Avicenna prescribed medication that can correct
the disorders of water metabolism (thirst-quenching) and
changes in the cardiovascular and nervous systems, as well as
the internal organs [137]. Tactics of treatment of diabetes by
Avicenna targeted correcting the process of diabetogenesis itself
and impaired renal function and liver, which perform excretory
functions, i.e. correction of acid-base status. Thus, these therapy
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tactics restored numerous functions of the endothelium.
Simple and complex anti-diabetic herbal remedies
recommended by Avicenna are of particular interest. All
medicines and medicinal plants are characterized by Avicenna in
the framework of the mizajdoctrine and in accordance with the
requirements of the two ancient pharmacological laws—therapy
tactics “opposite with opposite” and “like with like.” The fact
that all recommended antidiabetic agents were of natural origin
is another distinctive feature of Avicenna’s medical tactics in
comparison with the modern approaches to diabetes treatment.
Those agents had low toxicity and did not cause adverse effects
on the liver, kidneys and other internal organs. Moreover, their
curative effect was aimed at restoring normal organs functions,
as well as contributing to the purification of body fluids and the
endothelium.
9.2. Natural products used to treat diabetes
We have compiled a list of medicinal plants, minerals and animal
products recommended by Avicenna for etiopathogenetic,
auxiliary and symptomatic treatment of diabetes and related
diseases. We identified Russian and Latin names of medicinal
plants recommended by Avicenna as antidiabetic agents. We
used a combination of medieval and contemporary sources to
identify plants including the “Tajik Thesaurus Medical Dictionary
at-Tanvir” of Kamari Bukhari (X century); “Kitab Saydana”
(Pharmacognosy) of Abu Rayhan Beruni and “Hakoik-ul-adviya”
(Pharmacopoeia) of Abumansur Muwafaq Ali Hiravi (X century).
Latin names of 75 medicinal plants were confirmed based on
the description and cross-referenced in the “International Code
of Botanical Nomenclature” and multi-volume “Flora of Bulgaria
and the Soviet Union [138].”We consultedweb-based databases,
including International Plant Names Index; U.S. Department
of Agriculture, Agricultural Research Service, Beltsville Area;
Biodiversity Heritage Library; Royal Botanical Gardens Kew;
Royal Botanical Gardens Edinburgh; European Environment
Agency; Integrated Taxonomic Information System; and Tropicos.
The list of most common antidiabetic plants is presented list of
plant species most commonly referred by Avicenna for diabetes
treatment: Acacia arabica (Lam.) Willd., Acacia nilotica (L.)
Delile, Alhagi maurorum Medik., Aloe vera L., Alpinia
officinarum Hance,
Althaea officinalis L., Armeniaca
vulgaris Lam., Artemisia L. multiple species, Astragalus
tragacantha L., Berberis vulgaris L.,
Boswellia carteri
Birdw., Cerasus vulgaris Mill., Chamomilla recutita (L.)
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Cinnamomum cassia (L.) J. Presl, Cistus ladaniferus
Curtis, Citrus limon (L.) Burm. Fil., Commiphora
myrrha Engl., Coriandrum sativum L., Crocus sativus
L., Cucumis sativus L., Cucurbita maxima Duchesne,
Cupressus sempervirens L., Cydonia oblonga Mill.,
Cynara scolymus L., Cyperu srotundus L., Daucus
carota L., Ecballium elaterium (L.) A.Rich., Ferula
foetida Regel, Foeniculum vulgare Mill., Geranium collinum
Stephan ex Willd., Glycyrrhiza glabra L., Hordeum vulgare L.,
Hypericum perforatum L., Iris germanica L., Lactuca scariola
L., Malabaila pumila Boiss., Matricaria chamomilla L., Mentha
arvensis L., Nymphaea alba L., Origanum dictamnus L.,
Phaseolus vulgaris L., Pimpinella anisum L., Plantago psyllium
L., Portulaca oleracea L., Potentilla reptans L. Prunus
domestica L., Punica granatum L., Pyrus communis L.,
Rhus coriaria L., Rosa cinnamonea L., Rosa damascena P.
Mill., Silybum marianum (L.) Gaertn., Syzygium aromaticum
(L.) Merr. & L. M. Perry, Thymus glaber Mill., Triticuma
estivum L., Triticum vulgare Vill., Viola odorata L., Vitis vinifera
L.,
The arsenal of medicines that Avicenna recommended for
diabetes therapy included 84 agents. Plant products accounted
for 75 items (89.3%), animal six (7.1%), and mineral tree,
(3.6%). Depending on the natural product properties was
performed either on herbal infusion (1plant material:10 water),
or freshly collected sap, or fresh juices (fruits). We measured pH
and evaluated the concentration of alkaline (potassium, sodium,
magnesium) and acidic (Cl-, PO 43-, SO42-) equivalents and some
organic acids. Using these results, we classified all 84 antidiabetic
herbs and animal and mineral agents in two groups: acidic (cold
mizaj) and alkaline (hot mizaj). The absolute majority of tested
substances (92%) belonged to alkaline (hot mizaj). This includes
allof the mineral and plant products with the exception of the
fruit juice of two plant species, Rosa cinnamonea L
(cinnamon rose, pH 1.8-2.8) and Citrus limon (L.) Burm.
Fil. (lemon, pH around 2.3-3.4).
The results of the scientific analysis of Avicenna’s doctrine,
dedicated to the issues of ilaj-bil-Tadbeer, Ilaj-bil-Ghiza and IlajbilDawa of diabetes, showed that in the first place, A vicenna
recommended diet correction (Ilaj-bil-Ghiza) and then medicinal
treatment. Along with simple vegetable, animal and mineral
remedies (Ilaj-bilDawa), Avicenna used 20 complex products
consisting of two or more components for the treatment of
severe forms of diabetes.
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9.3. Developing botanical therapeutics based on
Avicenna’s ideas
Our preliminary analysis showed that in ecologically clean
mountainous regions of Tajikistan, more than 40 species of
medicinal plants with active metabolism corrective properties,
including antidiabetic, are growing. Many polyphenol- and
flavonoid-containing plants have, along with a hypoglycemic
effect, active hepatoprotective, nephroprotective, antioxidant,
angioprotective, immunostimulant or adaptogenic effects.
Therefore, creation of new plant polyphenols containing herbal
remedies may provide fundamentally new effective antidiabetic
agents with metabolism-corrective effects, improving liver,
kidney, and pancreas functioning (Figure 1), as well as actively
suspending the process of diabetogenesis. Widely distributed in
Tajikistan,G. collinum is a medicinal plant mentioned by Avicenna
for diabetes treatment and has been used in traditional medicine
for the treatment of rheumatism, gout, dysentery, skin wounds,
eczema and external and internal bleeding. The plant’s total
polyphenolic compounds 349.84 mg GAE/g, flavonoids 96.07
mg QE/g, antioxidant activity IC50 11.21 µg/mL, antidiabetic
activity (PTP-1B) IC50 0.10 µg/mL and (α-Glucosidase) IC50 0.07
µg/mL were measured using a 50% aqueous-ethanolic extract. In
addition 10 biologically active compounds were elucidated from
the root of G . collinum by analyzing their spectral data (MS, 1H
and 13C-NMR, including HMQC, HMBC and DEPT): 3,3’,4,4’tetra-O-methylellagic acid, 3,3’-di-O-methylellagic acid, caffeic
acid, quercetin, (+)-catechin, (–)-epicatechin, (–)epigallocatechin, gallic acid,β-sitosterol-3-O-β-Dglucopyranoside and corilagin [114].
Within the framework of Avicenna’s approach to diabetes
management new botanical therapeutics have been developed
at IAMP. For example, Novobet, a concoction of roots of
G. collinum, G. glabra and fruits of R. coriaria, inalloxaninduced diabetic rabbits demonstrated significant activity in
reducing hyperglycemia. An oral dose of 5 ml/kg
Novobet infusion resulted, at seven, 15 and 30 days of
treatment, in serum glucose level reductions, compared with
untreated animals. In addition, serum concentration of total
lipids, cholesterol, triglycerides and malondialdehyde decreased
and HDL level increased [139].
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Conclusion and discussion.
Even a millennium later, we have a lot to learn from the
evidence-based medical approach of Avicenna [3, 6, 117]. A
conventional, comprehensive approach to the prevention and
treatment of diabetes relies on a growing understanding of
glucose metabolism and regulatory pathways (Figure 1). Multiple
glucose-reducing medicines differ in efficacy, ease of use,
negative side effects and cost. The potential of a therapy “cost”
involves more than just a cost-benefit analysis. It is based on
the set of attributes that takes into account the long-term safety
and tolerability, risk of hypoglycemia, weight gain and suitability
of using it in a presence of comorbidities. Individualized therapy
should take into account the needs and preferences of patients,
based on their circumstances, their understanding and their
commitment. Now, as in Avicenna’s times, for tolerant, adequate
pharmacotherapy, an individual approach is required to assess
goals of treatment and to achieve them in the safest way.
Consequently, for the purposes of effective treatment of T2DM
and prevention of severe complications we need to integrate
Western and complementary medicines.
In both in Avicenna’s and contemporary approaches,
diet plays a major role in the prevention and management of
diabetes. Plant-based foods such as fruits and vegetables are
a key source of potassium and magnesium, major contributors
to the dietary alkali load. Numerous studies have reported
the putative association of the consumption of specific food
products, or their constituents, with the incidence of diabetes,
and mounting evidence now suggests that some dietary factors
can improve glycemic regulation. Foods and dietary constituents
have been shown to act through multiple pathways and may
exhibit a variety of modes of action including inhibition of
carbohydrate-hydrolyzing enzymes, intestinal glucose transport,
hepatic glucose output, delay of gastric emptying and/or
intestinal absorption of carbohydrates [140, 141]. Food products
and dietary constituents may modulate the incretin effect,
stimulate glucagon-like peptide-1 (GLP-1) secretion or inhibit
dipeptidyl peptidase-IV (DPP-IV). Some dietary constituents
mimic insulin action, affect insulin release or sensitivity, or inhibit
protein tyrosine phosphatase 1B (PTP1B). They also may activate
the peroxisome proliferator-activated receptor gamma (PPAR-γ),
demonstrate insulin mimetic action or stimulate insulin secretion
[141].
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The majority of medicinal plants have never been tested
against ever-growing numbers of molecular targets (Figure 1).
Medicinal plants are multifaceted, adaptive, environmentally
interactive systems exhibiting synergy and nonlinear healing
causality [142]. Recently, Western science and indigenous
science appear as equally valid notions to guide emergent
research practices [110]. Many herbal medicines are now being
supported by scientific evidence and have been shown to exert
significant effects in the body, relieve symptoms, treat disease
and improve everyday function. Diverse natural compounds have
been shown to affect cardiovascular and metabolic disorders
via different mechanisms, such as anti-inflammatory activity,
improvement of blood lipid profiles, improvement of insulin
sensitivity, or normalization of blood glucose levels. However,
only a few molecular targets or pathways are well-established
to mediate the beneficial effects of natural compounds in the
context of cardiovascular and metabolic disorders. Selected
examples include the AMP-activated protein kinase (AMPK),
cyclooxygenase (COX)-1 and -2, the dipeptidyl peptidase-4
(DPP-4), eNOS, the transcription factors NF-κB, nuclear factorerythroid 2-related factor 2 (Nrf2), and PPAR, the PTP1B, and
5-lipoxygenase (5-LO) [143, 144]. For a variety of medicinal plants
used in many traditional medicines, the mechanisms of action
have not yet been elucidated. Scientists routinely accumulate
large sets of data produced by advanced technologies. Hence,
computational approaches and advanced synthetic techniques
may be effectively utilized in developing botanical therapeutics
[111].
A recent review summarized that medicinal plants
used in Persian medicine, including many used by Avicenna
for prevention and treatment of diabetes performed their
therapeutic effects via various well-established pharmacological
mechanisms of actions. Established modes of actions encompass
multiple cellular mechanisms, including regeneration of
pancreatic β-cell, limitation of glycogen degradation and
gluconeogenesis and anti-inflammatory, immunoregulatory,
antiapoptosis, antioxidative stress, as well as modulation of
intracellular signaling transduction pathways [145]. In the
current paper, we also demonstrated how anin-depth analysis
and new interpretations of the 1,000-year-old text may lead
to new approaches to the search for diabetes prevention and
treatment. Naturally, the efficacy of medicinal herbs needs to be
established, and toxicity, contraindications and side effects also
214
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need to be investigated.This is best done with clinical research
and trials that are being conducted almost exclusively on efficacy
and are limited in number, probably because of a lack of funding.
Very little to no attention is being given to more traditional fresh
herbal extracts [146].
It is essential to monitor the quality of botanical therapeutics
and adapt the use of medicinal plants to modern conditions.
The quality of the botanicals can be significantly improved
by implementing good agricultural practices at the point of
cultivation of medicinal plants and good practices during the
manufacturing and packaging of finished herbal products, as
well as post-marketing quality-assurance surveillance [147].
Clinical evaluation of botanical therapeutics remains an
important issue. Collaborative partnerships offer the context and
process by which many of the ethical challenges in international
herbal medicine research can be resolved [148]. The Fogarty
International Center of the National Institutes of Health plays
an important role in cross-training investigators and investing
in safety-monitoring infrastructure, which helps promote ethical
international herbal medicine research. Comprehensive analysis
of Avicenna’s approach to the treatment of prediabetes and
diabetes provides valuable directions in the search for plantbased treatments. Botanical therapeutics may provide relatively
inexpensive, safe methods for diabetes treatment. This is even
more important for developing countries with limited resources.
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